Consultation
Dr. Farag reviews your medical history, orders baseline metabolic labs, and performs a body composition analysis to design your personalized GLP-1 protocol.
GLP-1 Therapy - Semaglutide & Tirzepatide in Fort Myers, FL
FDA-Approved Weight Loss Injections
Your GLP-1 Therapy - Semaglutide & Tirzepatide at a glance:
Treatment Time:15-30 minutes
Results Onset:4-8 weeks
FDA Approved:Yes
Administration:Weekly injection
Why Diets Fail and GLP-1 Therapy Succeeds
Biology Over Willpower
For millions of adults in Fort Myers and Southwest Florida, weight loss feels impossible despite genuine effort. Caloric restriction triggers hormonal adaptations - increased ghrelin, decreased leptin, and metabolic slowdown - that actively work against sustained weight loss. Studies show that over 80% of people who lose weight through diet alone regain it within five years. This is not a failure of discipline; it is a predictable biological response that makes long-term success nearly unattainable without medical intervention.
GLP-1 receptor agonists like semaglutide and tirzepatide work with your body's own signaling systems to reduce appetite, slow gastric emptying, and improve insulin sensitivity. Clinical trials demonstrate average weight loss of 15-20% of body weight over 68 weeks. At RegalMed Clinic, Dr. Sherry Farag designs personalized GLP-1 protocols that address each patient's unique metabolic profile, ensuring safe dose titration, nutritional support, and sustainable lifestyle changes alongside medication therapy.
What Is GLP-1 Therapy?
The Science of GLP-1 Receptor Agonists
GLP-1 therapy uses injectable medications - semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) - that mimic the glucagon-like peptide-1 hormone your body naturally produces. These FDA-approved medications bind to GLP-1 receptors in the brain, pancreas, and gut to reduce appetite, enhance satiety, improve glycemic control, and promote fat metabolism. Semaglutide received FDA approval for chronic weight management in 2021, while tirzepatide - a dual GIP/GLP-1 receptor agonist - was approved for obesity in 2023.
Tirzepatide uniquely activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing enhanced metabolic effects. In the SURMOUNT-1 trial, tirzepatide patients achieved up to 22.5% body weight reduction at the highest dose. Semaglutide 2.4 mg demonstrated 14.9% weight loss in the STEP 1 trial. Dr. Farag also offers compounded semaglutide in Fort Myers for patients who may benefit from customized dosing or improved access. All protocols include regular metabolic monitoring and personalized titration schedules.
Treatment Timeline
Treatment Time
15-30 minutes per visit
First Signs
4-8 weeks (appetite changes within days)
Full Effect
6-12 months (peak weight loss)
Maintenance
Ongoing or transition protocol
Benefits of GLP-1 Therapy
Evidence-Based Advantages
- 01
Clinically Proven Weight Loss
Average 15-22% body weight reduction demonstrated in large-scale FDA clinical trials
- 02
Reduced Cardiovascular Risk
Semaglutide shown to lower major adverse cardiovascular events by 20% in the SELECT trial
- 03
Improved Metabolic Health
Lowers HbA1c, fasting insulin, triglycerides, and systemic inflammation markers
- 04
Sustainable Results
Weekly dosing with physician-guided titration promotes adherence and long-term success
- 05
Appetite Control
Reduces hunger and food noise through central nervous system GLP-1 receptor activation
GLP-1 Therapy vs Alternatives
Treatment Comparison
| Treatment | Mechanism | Time | Results | Duration | Downtime | Best For |
|---|---|---|---|---|---|---|
| GLP-1 Therapy | GLP-1/GIP receptor agonism | 15-30 min/visit | 15-22% weight loss | Ongoing | None | Obesity, metabolic syndrome |
| Peptide Therapy | Growth hormone secretagogues | 10-15 min/visit | Fat loss + lean mass | 3-6 month cycles | None | Body recomposition, recovery |
| Emsculpt Neo | HIFEM + RF energy | 30 min/session | 30% fat reduction | 4 sessions | None | Targeted fat + muscle building |
Who Is a Good Candidate for GLP-1 Therapy?
Candidacy and Considerations
GLP-1 receptor agonist therapy is most effective for adults who have struggled with weight management despite consistent lifestyle efforts. Dr. Farag evaluates each patient's full metabolic profile, medical history, and weight loss goals to determine the most appropriate medication and dosing strategy.
Ideal Candidates for GLP-1 Therapy
- Adults with BMI of 30 or greater (obesity classification)
- Adults with BMI of 27+ with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
- Patients who have not achieved sustained weight loss through diet and exercise alone
- Individuals motivated to combine medication with lifestyle modifications
- Patients seeking improvement in metabolic markers alongside weight loss
Who Should Wait or Avoid GLP-1 Therapy
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis or active gallbladder disease
- Pregnancy, planning pregnancy, or breastfeeding
- Severe gastroparesis or gastrointestinal obstruction
- Known hypersensitivity to semaglutide, tirzepatide, or any excipient
Dr. Farag conducts a thorough medical evaluation including laboratory work before initiating any GLP-1 protocol. Patients with a history of thyroid nodules, renal impairment, or retinopathy require additional screening and close monitoring throughout treatment.
GLP-1 Therapy Treatment Overview
Initiation
Dr. Farag starts you on a low dose of semaglutide or tirzepatide, with gradual titration over 4-8 weeks to minimize gastrointestinal side effects.
Weekly Injections
You receive a subcutaneous injection during brief weekly or biweekly visits, with Dr. Farag monitoring your response and adjusting dosing as needed.
Progress Monitoring
Regular body composition scans, metabolic panels, and check-ins with Dr. Farag ensure you're on track and allow protocol adjustments for optimal results.
GLP-1 Therapy Side Effects
Risks and Safety
GLP-1 receptor agonists are FDA-approved with well-established safety profiles from extensive clinical trials involving over 25,000 participants. The most common side effects are gastrointestinal and typically resolve as your body adjusts to the medication.
Common Side Effects
- Nausea (most frequent, usually mild and transient during dose escalation)
- Diarrhea or constipation
- Decreased appetite (therapeutic effect)
- Abdominal discomfort or bloating
- Injection site reactions (redness, mild swelling)
Less Common but Serious Risks
- Pancreatitis (rare; discontinue if severe abdominal pain occurs)
- Gallbladder events including cholelithiasis
- Hypoglycemia (primarily when combined with sulfonylureas or insulin)
- Thyroid C-cell tumors observed in rodent studies (boxed warning; clinical relevance in humans uncertain)
Dr. Farag's gradual titration protocol and regular monitoring significantly reduce the incidence and severity of side effects. All patients receive detailed safety counseling before starting therapy.
GLP-1 Therapy Cost in Fort Myers
Pricing and Payment Options
GLP-1 therapy pricing at RegalMed Clinic varies based on the specific medication, dosing requirements, and treatment duration. Dr. Farag works with each patient to find the most effective and accessible option.
Estimated Pricing
Semaglutide (compounded)
Starting at $299-$499/month
Tirzepatide (compounded)
Starting at $399-$599/month
Initial Consultation + Labs
Varies by panel
Body Composition Monitoring
Included with program
Pricing includes medication, weekly or biweekly visits, dose titration management, and ongoing physician supervision. RegalMed Clinic offers compounded semaglutide in Fort Myers as a more affordable alternative to brand-name Wegovy. Insurance coverage varies by plan and diagnosis. Our team can help verify your benefits.
Contact RegalMed Clinic at (239) 395-2434 for a personalized cost estimate based on your specific needs and treatment goals.
Why Choose RegalMed Clinic for GLP-1 Therapy
Fort Myers, FL
Board-Certified Physician
Every protocol designed and supervised by Dr. Farag, M.D. - not a nurse-only clinic
Personalized Dosing
Individualized titration schedules based on metabolic labs, tolerance, and weight loss goals
Comprehensive Monitoring
Regular body composition analysis, metabolic panels, and progress assessments included
Compounded Options
Access to compounded semaglutide in Fort Myers for customized dosing and improved availability
Related Services
Body Contouring
Regenerative Medicine
GLP-1 Therapy FAQ
Frequently Asked Questions
01 How does semaglutide work for weight loss?
Semaglutide mimics the GLP-1 hormone, activating receptors in the brain that regulate appetite and satiety. It slows gastric emptying, reduces hunger signals, and improves insulin sensitivity. Clinical trials show an average 14.9% body weight reduction over 68 weeks when combined with lifestyle modifications.
02 What is the difference between semaglutide and tirzepatide?
Semaglutide targets GLP-1 receptors only, while tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two metabolic pathways simultaneously. Tirzepatide has shown slightly greater weight loss in clinical trials (up to 22.5% vs 14.9% for semaglutide). Dr. Farag will recommend the best option based on your metabolic profile and goals.
03 How much weight can I lose on GLP-1 therapy?
Clinical trials demonstrate average weight loss of 15-22% of body weight over 12-18 months. Individual results depend on starting weight, medication choice, dosing, adherence, and concurrent lifestyle changes. Dr. Farag monitors your progress with body composition analysis and adjusts your protocol for optimal results.
04 Are there side effects of GLP-1 therapy?
The most common side effects are gastrointestinal: nausea, diarrhea, and constipation, which typically improve within 4-8 weeks as your body adjusts. Dr. Farag uses a gradual dose titration schedule to minimize these effects. Serious side effects like pancreatitis are rare but monitored for at every visit.
05 Do you offer compounded semaglutide in Fort Myers?
Yes. Regal Med Clinic offers compounded semaglutide as a more accessible and cost-effective option for qualifying patients. Compounded formulations are prepared by licensed 503B pharmacies under physician oversight. Dr. Farag evaluates whether compounded or brand-name medication is the best fit for your needs.
Location15750 New Hampshire Ct, STE D
Fort Myers, FL, 33908
Fort Myers, FL, 33908
Phone(239) 395-2434
Schedule Your GLP-1 Therapy - Semaglutide & Tirzepatide Consultation
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. (PMID: 33567185) - Semaglutide 2.4 mg produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. (PMID: 35658024) - Tirzepatide achieved up to 22.5% weight reduction at the highest dose over 72 weeks.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. (PMID: 37952131) - Semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity.
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. (PMID: 33755728) - Continued semaglutide treatment maintained weight loss while withdrawal led to regain.
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. (PMID: 34170647) - Tirzepatide demonstrated superior glycemic control and weight loss compared to semaglutide 1 mg.